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I. ASYMPTOMATIC BACTERIURIA IN HEALTHY AND DIABETIC 
POPULATIONS 
 
Urinary tract infections (UTIs) are among the most common bacterial infections 
in the healthy population. Up to 50% of women report having had at least one UTI in 
their lifetime. Uncomplicated UTIs occur most often in young healthy adult women and 
are easy to treat. However, in other patients groups, UTIs can have a complicated 
course, are more difficult to treat and often recur. Complicated UTIs occur most 
commonly in patients with abnormal genitourinary tract. However, other conditions 
such as old age, immunosuppressive treatment, immunocompromised state and diabetes 
mellitus also predispose to an enhanced susceptibility for the development of UTI with 
complicated course (1).  
UTI is a significant problem in patients with diabetes mellitus because of the 
multiple effects of this disease on the urinary tract and host immune system. 
Complicated UTIs associated with diabetes include renal and perirenal abscess, gas-
forming infectios, such as emphysematous pyelonephritis and emphysematous cystitis, 
fungal infections and renal papillary necrosis (2). The chronic consequences of diabetes 
on the genitourinary system are generalized vascular disease (including renal artery 
stenosis), diabetic nephropathy, diabetic neuropathy resulting in bladder dysfunction, 
different degree of glucosuria and abnormal function of the immune system (2). In 
general, patient history is helpful in the localisation of the infection. The symptoms of 
lower UTI include dysuria, frequency, urgency, small-volume voids or lower abdominal 
pain. On the other hand, upper UTI is characterized by fever, nause, vomiting, flank 
pain or costo-vertebral tenderness (3). Widespread acceptance and application of the 
quantitative urine culture identified several patient populations who were clinically 
 5
asymptomatic but had high prevalence of positive urine cultures. These included 
pregnant women, individuals with urological abnormalities, patients with indwelling 
urethral catheters and some diabetic patients. This entity is called asymptomatic 
bacteriuria (ASB). 
 
I/1. Definition of asymptomatic bacteriuria 
Acceptable methods for urine collection include midstream clean-catch, 
catheterization and suprapubic aspiration. The first method is preferred for routine 
collection of urine for culture. If there are more than 105 colony-forming units 
(CFU)/ml in a clean-catch urine, there is 80% probability that it is true bacteriuria. If 
two different samples demonstrate the same specimen at least 105 CFU/ml, the 
probability increases to 95% (4).  
The term ASB refers to the presence of two consecutive, freshly voided, 
midstream, morning urine specimen both yielding positive cultures (≥105 CFU/ml) of 
the same bacterium, in a patiens without urinary symptoms (5). According to the 
guideline of Infectious Disease Society of America in asymptomatic men a single 
isolated specimen in a quantitative count ≥105 CFU/ml is sufficient to diagnose ASB 
(5). If the bacterial count is between 10 and 104/ml usually contamination is considered 
in spontaneous voided urine (4).  
It is not well understood why patiens with ASB do not develop symptoms, while 
the organisms are the same types of bacteria that cause UTI. One possible mechanism is 
that bacteria with decreased virulence may colonize the urine rather than cause a 
symptomatic infection (6). 
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I/2. Asymptomatic bacteriuria in non-diabetic populations 
I/2.1. Prevalence  
In the healthy population the prevalence of ASB is represented in Figure 1. (5, 
7). It is less than 1% in full-term female neonates. Male neonates are more often 
affected than females (∼2%). The presence of bacteriuria in neonates is an indication for 
investigation to rule out congenital malformations, especially vesico-ureteral reflux. 
After infancy the prevalence of ASB decreases mainly in boys and in preschool children 
it occurs in approximately 1% of girls and ASB is very rare in boys (5, 6). In school-age 
girls the prevalence of ASB increases to 2-5% and it remains in this range during 
adulthood in sexually active women (5, 8). During pregnancy the occurance of ASB do 
not change, but the consequences are more serious than in non-pregnant women. In 
young adult men the prevalence of ASB is below 0.01%. In the elderly, the prevalence 
of bacteriuria ranges from 17 to 50% in women and 6-34% in men (5, 6). 
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Figure 1.: The prevalence of ASB in healthy women and men (5, 7). 
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I/2.2. Risk factors of ASB in non-diabetic populations 
All neonates are considered to be immunocompromized, therefore they are at a 
higher risk to any types of bacterial infections. Renal developmental abnormalities 
which are diagnosed mainly during infancy, but can be discovered in any age-group 
may predispose to bacteriuria. In non-pregnant young women, ASB is strongly 
associated with sexual activity. In a prospective study from Hooton et al. the recent use 
of diaphragm plus spermicide and recent sexual intercourse remained associated with 
ASB in multivariate analysis (8). In the elderly, some comorbid conditions appear, such 
as obstructive uropathies, debility, neurogenic bladder, the use of indwelling catheters 
and incontinence which can contribute to the development of ASB in this population 
(9).  
 
I/2.3. Immunology and ASB 
When an invading organism reaches the uroepithelium it induces production of 
cytokines, especially interleukin-6 (IL-6) and interleukin-8 (IL-8) (10). IL-6 belongs to 
the heat shock proteins synthesized by T-cells, B-cells, endothelial cells, fibroblasts, 
macrophages and epithelial cells and stimulates the liver to produce proteins that are 
responsible for acute-phase response. IL-8 is a small (∼8 kDal) cytokine which is 
produced by macrophages, endo- and epithelial cells, and it works as an inducer of 
neutrophil chemotaxis (10). Agace et al. examined the role of IL-8 in the pathogenesis 
of uroinfection. Women with a history of recurrent symptomatic UTI were colonized 
with E. coli. Urine samples were collected for IL-8 determination and epithel cells were 
isolated from the „infected” urine for stimulation by pathogens in vitro. There was no 
IL-8 production before bacterial installation. IL-8 secretion was rapidly (within 3 hours) 
observed at the onset of UTI, before appearance of the neutrophil influx in the urine. 
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After bacterial stimulation of the isolated kidney and bladder epithelial cells, it has been 
shown by immunofluorenscence staining that each type of cells produce IL-8 response 
locally (11). It also seems that the IL-8 is produced only in the presence of pathogenic 
agents, because in the case of other inflammatory renal diseases like glomerulonephritis 
IL-8 was not detected in the urine (12). 
IL-8 levels are consistently elevated in the urine of patients with UTI and ASB 
but they are undetectable in the urine of controls (10, 13). However, at the same time, 
the IL-8 levels was not elevated in the sera, which also suggests that IL-8 is secreted 
locally, not filtrated from the blood (13). Systemic lipopolysaccharide (LPS) injections 
in healthy volunteers did not cause significant increase in the urine chemokine levels, 
despite a transient increase in the systemic chemokine concentration (14). By 
immunhistochemistry it was shown that epithelial cells from all parts of the human 
urinary tract contain IL-8 and this production is constitutive, but the secretion is induced 
by pathological process (eg.: malignancy, infections) (15). Jantausch et al. have shown 
that after introducing antibiotics the IL-8 level decreased significantly in children with 
UTI (16). The mean decrease of IL-8 after antibiotic treatment was 25% after the first 
dose of antibiotic and more than 80% after at least 2 days of treatment in children with 
pyelonephritis (17). 
IL-6 as an acute-phase reactant also plays an important part in the mechanism of 
UTI. It seems that IL-6 is elevated in the serum in febrile UTI and its concentration is 
correlated with C-reactive protein levels. However, in ASB the elevation of IL-6 in the 
blood and often in the urine, as well was found to be not significant (18, 19). 
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I/2.4. Genetic studies and ASB/UTI 
There are some evidence that the predisposition for UTI is the genetically 
determined (20). Animal models of UTI have contributed to the understanding of host-
bacterial interaction during infectious process. LPS non-responder mice (C3H/HeJ) 
have general deficiency in cellular responses including neutrophil recruitment that 
might explain their inability to clear infections (21).   
C-X-C chemokines are members of four chemokine subfamilies (Figure 2.) In 
their molecular structures the first two, highly conserved cysteine residues are separated 
by a single amino acid nearest to the N-terminal of the protein (22). IL-8 binds to 
leukocytes by CXC-receptor-1 and -2 expressed almost exclusively on the surface of 
neutrophils (22, 23). CXCR-2 binds a broad spectrum of CXC-chemokines with low 
affinity, whereas CXCR-1 selectively binds to IL-8 with high affinity (22, 23). In 
experimental UTI the neutrophils of IL-8 receptor knockout mice failed to cross the 
epithelial barrier of the urinary tract and accumulated in the subepithelial tissue (24). In 
humans, the roles of CXCR-1 and CXCR-2 were studied in many diseases including 
sepsis, pulmonary-, gastrointestinal- and urinary tract diseases (25-29). Decreased 
expression or down-regulation of these receptors can lead to impaired neutrophil 
function, therefore it may play an important role in susceptibility to diseases mentioned 
above. In a Swedish study, CXCR-1 was examined in children with chronic 
pyelonephritis. At the time of the measurement of CXCR-1 expression the children 
were in an infection free period, therefore the CXCR-1 expression was not influenced 
by acute exacerbation of the UTI. As compared to healthy controls, they had reduced 
CXCR-1 expression. This finding also suggested a defect of innate host defense 
mechanism of this subpopulation (29). 
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Figure 2.: The members of chemokine subfamilies (22). 
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 In an other study, there was no difference in the expression of CXCR-1 between 
premenopausal healthy women and those with recurrent UTI (30). Recently, Lundstedt 
el al. examined the pedigrees of UTI-prone families and the possible association with 
CXCR-1 expression. They found that acute pyelonephritis was present in 15% in the 
medical history of family members of children with acute pyelonephritis, but only in 
3% of relatives of control subjects. This association was not present in patient with 
cystitis. They pointed out that CXCR-1 expression was significantly lower in patients 
and their family members compared with controls and suggested that low CXCR-1 
expression could be one of the inherited factors predisposing to acute pyelonephritis 
(31). There are five known CXCR-1 single nucleotide polymorphisms which are 
associated with reduced binding of transcription factors and thus resulting in increased 
susceptibility to UTI (32). 
Of course, other candidate genes were also examined which could be involved in 
the pathomechanisms of UTI. Toll-like receptors (TLRs), one of the main members of 
innate immunity are expressed on the surface of mucosa and antigen presenting cells. 
These receptors have pivotal role in recognising highly conserved microbial patterns 
(such as LPS) and they are working as a pro-infammatory activators. Ragnarsdóttir et al. 
suggested that children with ASB have decreased TLR4 expression leading to weak 
mucosal response to urinary pathogens, which could promote asymptomatic state 
instead of symptomatic UTI (33). 
The question, why an infection in the urinary tract progresses to acute 
pyelonephritis in one individual and causes only asymptomatic bacteriuria in an other 
one, is very intriguing. The two different pathomechanisms are demonstrated in Figure 
3. (34). Invasive microbial strains (including uropathogenic E. coli with P fimbia) in 
individuals with normal innate immune mechanisms or attenuated stains in hosts with 
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deficient defense mechanisms causes acute pyelonephritis. If the immune response is 
normal, renal scarring will not develop (Figure 3a.). Bacterial presence in the urinary 
tract remains asymptomatic when bacteria with low virulence factors infect the 
immunocompetent host or if the more virulent pathogens invade the mucosa of a host 
with decreased TLR4 expression (Figure 3b.) (34). 
 13
 
Figure 3.: Different pathomechanism in acute pyelonephritis and ASB (explanation in the text, 
UPEC: uropathogenic Escherichia coli) (34).
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I/2.5. Treatment of ASB in non-diabetic populations 
 
 In subjects with normal urinary tract the possibility of renal scarring, declining 
renal function and hypertension due to ASB is very low (5, 35).  
Fifty infants with bacteriuria were followed for 6 years in a Swedish study. Two 
of the children developed pyelonephritis during the follow-up period and 36 children 
had spontaneous resolution form ASB. None of the participants developed renal damage 
or had deteriorating renal concentrating capacity (36).  
In a prospective study, ASB was found to be a risk factor for symptomatic UTI 
in healthy young women. 8% of those with ASB developed symptomatic urinary 
infection within a week. In contrast, only 1% of non-bacteriuric women had UTI. This 
difference remained at the same level after 1 month (8). After 15 years of follow-up, 
55% of women with ASB at initial screening, developed urinary symptoms at least 
once. This happened only in 10% of non-bacteriuric women (37). A prospective, 
randomized, controlled trial examined the effect of a 1-week treatment with 
nitrofurantoin on ASB and found lower prevalence of bacteriura after 6 month, but not 
after 1 year after therapy as compared to the placebo group (38). According to the 
guideline of the Infectious Disease Society of America (IDSA) the treatment of ASB 
neither decreases the frequency of UTI nor prevents further episodes of ASB in 
premenopausal, non-pregnant women. Therefore, - they concluded - the screening for 
ASB is not indicated (5).  
In pregnant women, the consequences of ASB are more serious. In most 
patients, bacteriuria in pregnancy is due to pre-existing periurethral colonization rather 
than de novo infection during pregnancy (35). Pregnant women have a 20-30 fold risk 
for developing pyelonephritis during the last trimester and are more likely to experience 
premature labour or to deliver a low-birth weight infant (5, 6, 37). Antimicrobial 
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treatment of ASB in pregnany decreased the prevalence of pyelonephritis from 20-35% 
to 1-4%, therefore the routine screening in early pregnancy and the treatment in positive 
cultures are recommended (5).  
The analysis of the IDSA revealed no benefit of screening and treatment of 
elderly with ASB living in community (5).  
Patients with ASB who undergo urologic procedures associated with mucosal 
bleeding have a higher risk for bacteremia, therefore, the screening and the treatment is 
mandatory in these cases (5).  
 
I/3. Asymptomatic bacteriuria in diabetic patients 
I/3.1. Prevalence 
Urinary tract infection (often asymptomatic) is a frequent clinical finding in 
adult diabetic patients particularly in women (39). The prevalence of ASB ranges 
between 9.1-29.3% in diabetic women and between 0.7-11.1% in diabetic men (39). 
The majority of investigators have reported approximately a three-fold higher 
prevalence of ASB among diabetic women than among non-diabetic women, but it 
seems that the prevalence of ASB in diabetic and non-diabetic men is more or less equal 
(39-41). The majority of data has been collected from patients with type 2 diabetes. 
Only few studies are available in diabetic children. Two articles are from the 1960’s, 
where unusually low prevalences of ASB (1.6-2%) were reported (42, 43). The last 
publication in English language evaluating the prevalence of ASB in diabetic children is 
from 1985. In this study, three of 304 girls and none of the 337 diabetic boys had 
bacteriuria (44).  
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I/3.2. Risk factors of ASB in diabetes 
 The prevalence of ASB among patients with diabetes has been correlated with 
several clinical characteristics. It seems evident that hyperglycaemia and subsequent 
glucosuria present optimal circumstances to bacterial colonisation in the urine and 
uroepithel, which can make diabetic patients susceptible to ASB or UTI. However, it is 
widely accepted that the development of ASB is not influenced by the type or duration 
of diabetes (39) and probably the quality of diabetes control measured by glycated 
hemoglobin (HbA1C) level is not a determinant factor in the prevalence of ASB (39, 40, 
45, 46). Few studies reported that elevated HbA1C level was present in the bacteriuric 
group (47, 48). There are no data available demonstrating that fasting glucose or a 
randomly measured glucose level (preferably at time of urine collection) was higher in 
patients with ASB. 
There are only in vitro experiments which found a positive correlation between 
the glucose concentration of the urine and the bacterial growth (49). Till now, this study 
was not confirmed by in vivo data (40, 41). 
Microvascular complications are often found after 5-10 years of diabetes 
duration. Diabetic retinopathy does not seem to increase the prevalence of ASB (39, 
50). The results are more contradictory in the cases of micro-, or macroalbuminuria, 
especially in type 2 diabetes. In type 1 diabetic women, the presence of 
microalbuminuria is independent from the ASB (40, 48, 50). In a Spanish study, the 
albumin excretion rate (AER) was examined in women with type 2 diabetes with or 
without bacteriuria. There was no difference in AER either between the two groups, or 
before and after treatment of ASB (51). Other studies found the prevalence of 
microalbuminuria higher among patients with ASB in type 2 diabetes (46). The 
correlation is clear in the case of macroalbuminuria, which is a risk factor of ASB, 
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independently from the type of diabetes (40, 46). Neuropathy the third main 
microvascular complication was found to be a risk factor to ASB in type 1 diabetes 
(40).  
Over 50% of men and women with diabetes have bladder dysfunction, mainly 
adult patients are affected with this complication (41). However, Hungarian authors 
have showed with urodynamic studies that asymptomatic diabetic children had longer 
time to first voiding sensation than that of control children. The average urinary flow 
was also significantly higher in diabetics than in healthy controls (52). The longer time 
of the voiding sensation can lead to higher volume of urine fraction which results in 
increased bladder capacity. Hyperglycaemia diminishes the detrusor contractility of the 
bladder, therefore the amount of residual urine increases, this retention may promote 
bacterial colonisation of the urinary tract (53). 
Tamm-Horsfall protein (THP) is a glycoprotein in normal human urine produced 
by cells of the thick ascending limb of Henle loop and the early portion of the distal 
convulted tubule. It may protect the urinary tract from uropathogens by inhibiting 
bacterial adherence especially type-1-fimbriae of Escherichia coli (54). It was shown 
that newly diagnosed type 1 diabetic children had decreased THP concentration which 
persisted for 1 year after diagnosis (55). The defect of this protective mechanism could 
also lead to ASB in diabetes. 
Several workgroups investigated the the potentially diminished functions of 
polymorphonuclear leukocytes (PMNs) in diabetes. However, the chemotaxis, the 
phagocytosis and the killing mechanisms were found to be normal in diabetic patients 
with ASB (56). In another study, isolated impairment of PMNs function was not 
detected, but global dysfunction was showed. Before stimulation of PMNs, the adhesion 
molecule expression, the phagocytosis and killing were more effective and it was 
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thought that this condition resulted in increased free radical production in the baseline 
state. After stimulation, however, no further increase was detected in these parameters 
(57). They found that hyperglycaemia alone was not a determinant factor of PMNs 
abnormalities. 
 
I/3.3. Consequencies of ASB in diabetic patients 
 The main question is whether ASB increases the risk of symptomatic UTI in 
diabetic patients and therefore contributes to the irreversible deterioration in kidney 
function? Unfortunately, there are only a few prospective, follow-up studies available in 
diabetic adults and none in diabetic children.   
For the diagnosis of ASB two urine cultures are needed. However, after 7-10 
days, the second culture will be positive only in about 65% (45). This observation 
supports the possibility of spontaneous resolution of ASB.  
Geerlings et al. found that type 2 diabetic women with ASB had relative risk 
(RR) of 1.9 to develop symptomatic UTI in a 18-month follow-up period. Similar 
association was not observed among type 1 diabetic women with bacteriuria (50). In a 
Spanish study examining type 2 diabetic women and men, ASB was present at baseline 
in 25.5% and 10.1%, respectively. Over a 12-month period among those with ASB 
67.6% of women and 76.5% of men developed symptomatic UTI. The RR for UTI was 
4.5 in women and 7.0 in men (58). In the longest follow-up study to date (36 months) 
50 diabetic (9 with type 1 diabetes) women with untreated bacteriuria participated (59). 
After the first year of follow-up 26% of the participants experienced spontaneous 
resolution or symptomatic UTI and in 36% of them the initially cultured organism 
persisted. The authors observed that in the group with spontaneous resolution the 
infecting pathogens were mainly gram positive organisms (78%) and leukocyturia was 
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less frequently present. The prevalence of ASB decreased rapidly, but after 9 months 
there was no further change, half of the participants remained bacteriuric. Half of the 
patients with spontaneous resolution and half of those with symptomatic, treated 
infection became reinfected again (59). 
Neither type 1, nor type 2 diabetic patients with ASB had a higher risk for 
development of hypertension and there was no deterioration in kidney function (39, 60). 
 
I/3.4. Treatment of ASB in diabetes 
Parallel with the follow-up studies, the treatment of ASB in diabetic patients 
seems to be less and less justified. Studies from the 1990s implicated that a 2-week 
course of antibiotic therapy was equivalent with a 6-week long regime administered 
earlier for eradication of ASB. After completing an antibiotic therapy, recurrence was 
often observed within 8 weeks and it was considered to be mainly reinfection rather 
than relapse (39). A prospective, randomized trial from Harding et al. examined 105 
diabetic women with ASB. Half of the participants were treated with 
trimethoprim/sulfamethoxazol, the other half received placebo (61). The short-term 
outcomes of this study were favourable, because after 3 days of treatment 94% of 
patients was considered as cured in the antibiotic group and only 8% in the placebo 
group. However, after a 36-month follow-up, the frequency of symptomatic UTI and the 
time of the first UTI were similar in the two groups. The majority of women (∼60%) 
had no symptomatic episodes, pyelonephritis developed in 11% of placebo group and 
6% of antibiotic group (61). It seems that antibiotic therapy cleared the bacteria during 
the administration period but did not decrease the numbers of symptomatic episodes.  
The current approaches to management are different in United States and in 
Europe. In the US, the treatment is recommended because of the frequency and the 
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severity of provoked symptomatic UTI. European physicians believe that the benefit of 
treatment is doubtful (40).  
      Our own view is that using antibiotics in ASB enhances the possibility of selection 
of new resistant, more virulent strains. The education of patients to recognise the 
symptoms of UTI is much more important. 
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II. AIMS 
 First of all, we wanted to determine the prevalence of ASB in a large cohort of type 1 
diabetic children and young adults and in healthy controls. 
 The second goal of our work study was to examine the possible differences in some 
antropometric and metabolic parameters between diabetic patients with and without 
ASB. 
 The next aim was to identify the types of microorganisms causing ASB in type 1 
diabetic patients and to evaluate the usefulness of the routine screening method of ASB. 
 Finally, we also wanted to find some immunological factors which could play an 
important role in the susceptibility to urinary infections in type 1 diabetic children. 
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1. III. PATIENTS AND METHODS 
 
 The aims of the thesis were examined in four large cohorts from the patients of 
the „Mestyán Gyula” Diabetes Ward, Department of Pediatrics, University of Pécs. The 
overlap between the cohorts is remarkable in point of participants. We needed some 
cohorts because the sampling and experiments were done in different time (2002-2006). 
It is usual practice in our department to annually hospitalize diabetic children 
and adolescents for assessment, reeducation and screening for micro- and 
macrovascular complications. This opportunity was used to collect urinary and blood 
samples not only for diagnostic purposes but also for research. Newly diagnosed 
diabetic children, patients with diabetic ketoacidosis and diabetic patients with known 
renal developmental abnormality were automatically excluded from the studies, except 
in the case when the effect of ketoacidosis was tested. None of the participants in the 
study groups had symptomatic infection or fever or received antibiotic treatment during 
a month before hosptalization. Informed consent was obtained from all participants and 
the studies were approved by the local ethics committee. 
 
III/1. Characteristics of patients and controls 
 
III/1.1. Participants in „Prevalence of ASB” study 
During the observation period (between January of 2002 and October of 2002) 
219 diabetic children and young adults were admitted in our department. Ten patients 
with newly diagnosed diabetes, 4 with ketoacidosis, 4 women who delivered earlier, one 
being on antibiotic treatment and one who was operated on for a femoral abscess were 
excluded (n=20) from this study. Three patients with known renal developmental 
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abnormalities were also excluded. We have to add here that abdominal ultrasonography 
was not performed routinely in all of our patients.  
 Altogether 196 eligible subjects participated in this study. 14 of these patients 
contributed only with one urine sample (nine of these were sterile, three was 
contaminated, in one 105 CFU/ml Streptococcus agalactiae, in another one >105 
CFU/ml Enterococcus species were grown). Two consecutive samples were collected 
from 182 type 1 diabetic patients, 4 patients were found to have contaminated samples 
(2 out of 4 had leukocyturia). The 14 diabetic patients with one urine sample and the 4 
with contaminated consecutive samples were excluded from further analysis (n=18; 7 
males). Their average age was 12.8 ± 5.3 years, the median (IQR) duration of diabetes 
was 4.4 (2.3-7.7) years. 
To assess the prevalence of ASB in type 1 diabetes data of 178 (86 males) type 1 
diabetic children and young adults were analysed. Their average age at the time of urine 
culture was 15.1 ± 5.9 years (range: 4.0-29.4) with 6.2 (3.0-10.1) [median (IQR)] years 
of diabetes duration (range: 0.5-25.9).  
329 healthy schoolchildren / young adults (medical students) were asked to serve 
as the control group. From 133 out of them only one urine sample was available. One 
hundred and ninety-six control children provided two consecutive samples, among them 
two were contaminated. Control patients with single urine samples (n=133) and those 
with contaminated samples (n=2) were excluded, their average age was 13.6 ± 5.1 
years. The average age of the 194 „true” control patients (103 males) was 14.4 ± 5.1 
years. The difference in age between patients and controls was not significant (p=0.19). 
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III/1.2. Participants in „Urinary cytokine” study 
137 diabetic children and young adults participated in the study and 178 healthy 
schoolchildren / young adults (medical students) were asked to serve as the control 
group. After excluding 4 diabetic patients with contaminated urine the final study group 
consisted of 133 diabetic and 178 control children. The diabetic group consisted of 66 
males and 67 females whose average age at the time of urine sampling was 15.6 ± 5.7 
years (range: 3.3-26.6) with 7.3 ± 4.7 years of diabetes duration (range: 0.5-23.4). The 
average age of the 178 control patients (94 males) was 14.1 ± 4.7 years (range: 3.7-
26.6). The diabetic subjects were significantly older than the controls (p=0.013).  
 
III/1.3. Participants in „CXCR-1 expression” study  
 One-hundred and ten type 1 diabetic children participated in the CXCR-1 study 
and 54 healthy schoolchildren / medical students were asked to serve as controls. The 
diabetic group consisted of 43 males and 67 females whose average age (± SD) was 
16.0 ± 5.3 years (range: 5.9-29.1) with 7.6 ± 5.5 years diabetes duration (range: 0.5-
23.5). The average age in the control group (22 males) was 15.1 ± 6.2 years (range: 6.1-
30.1). The differences in the sex ratio (p=0.84), and in the average age (p=0.33) 
between the groups were not significant. 
 
III/1.4. Participants in „Serum IL-8” study 
 This study group consisted of 79 type 1 diabetic children (28 males) (age: 15.3 ± 
4.7 years with 7.8 ± 5.0 years diabetes duration) and 40 healthy control (19 males) (age: 
12.7 ± 5.2; p=0.008 vs. diabetic children). 
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III/2. Urine sampling and cultures 
 After cleaning the genitalia and perineum of patients with three gauze sponges 
saturated by octemidine-dihydrochloride, midstream clean voiding morning urine 
samples were collected on two consecutive days. The urine samplings were performed 
(in patients younger than 12 years of age) or supervised (in patients older than 12) by 
qualified nurses in the same manner and place in both diabetic and control groups. After 
voiding of the urine the samples were divided into two parts. The smaller fraction of the 
urine samples was immediately centrifuged at 3500 rpm for 5 minutes and the 
supernatants were frozen and kept at –70°C until the measurement of urinary IL-6 and 
IL-8 levels. The remaining urine samples were stored at 4°C (9) until taken to the lab 
(within 2 hours), where the inoculation was carried out by a calibrated loop on eosin-
methylene blue and Colombia blood agar plates (Oxoid, UK). The results were read 
after 24 h incubation on 37°C. Diabetic patients were hospitalized for 3 days. The 
measurements of urinary interleukins were performed from the samples obtained on the 
first day. Urine samples on the second day were used only to diagnose asymptomatic 
bacteriuria and leukocyturia, but repeated measurements of interleukins were not 
performed. 
 
III/3. Definitions 
To diagnose ASB we used the criteria of the Infectios Disease Society of America 
(IDSA) (10). Briefly, asymptomatic bacteriuria was defined as the presence of ≥105 
CFU/ml (colony forming units) of one and the same bacterial species on two 
consecutive days without symptoms of urinary tract infection (UTI). Contamination was 
defined as the presence of at least two microorganisms in a sample or different bacteria 
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on the two consecutive samples. Subjects cultured CFU<105/ml with one and the same 
species were considered to be no-bacteriuria („sterile”). 
Leukocyturia was diagnosed with two methods. The semiquantitative method by 
microscope defined leukocyturia as >5 cells/high power field (hpf) at 400X 
magnification. The dip-slide method (Boehringer, Combur10-Test M, Roche Diagnostics 
GmbH, Mannheim, Germany) was also used. Leukocyturia was diagnosed if either the 
microscopic finding or the dip-slide test was positive. 
 
III/4. Measurement of urinary cytokine levels 
 The measurements were done in Department of Immunology and 
Biotechnology, University of Pécs. For immunoserological detection of human IL-6 and 
IL-8 level in urine samples we used optimized commercial OptEIA Sets (Pharmingen 
USA). Briefly, microtiter wells (NUNC Maxisorp P/N, Cat No. 442404) were coated 
with 100 µl per well of capture antibody overnight at 4oC. After 3 washing steps, the 
nonspecific binding sites were blocked with 200 µl/well 10% FBS/PBS buffer for 1 
hour at room temperature (RT). After 3 washing steps 100 µl of the standard, control 
and sample dilutions were pipetted into the appropriate wells and incubated for 2 hours 
at RT. After 5 washing steps 100 µl of the biotinylated second cytokine specific 
monoclonal antibody and the avidin-horseradish peroxidase complex (Working 
Detector) was added to each well and incubated for 1 hour at RT. After 7 washing steps 
the reaction was developed using ortho-phenylene-diamine (OPD) substrate solution. 
The absorbance was read at 490 nm within 30 minutes of stopping reaction. To 
calculate results the mean absorbance of zero standard was subtracted from the mean 
absorbance of duplicate standards. The standard curve was plotted using the best curve 
fit of our Labsystem EMS Reader Program MF V2.9-0. To determine cytokine 
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concentrations of the samples the calculated concentrations were multiplied by the 
dilution factor.  
The concentrations of urinary interleukins were corrected for creatinine, which 
were measured by the Jaffé method. The final concentration values were given in 
picogram per milliliter per milligram creatinine. The detection limits were 4.7 pg/mg 
creatinine for IL-6 and 3.1 pg/mg creatinine for IL-8. The intra- and interassay 
variability were less than 5%. 
 
 
III/5. Measurement of CXCR-1 
 
III/5.1. Neutrophil isolation 
 The measurements were done in Department of Immunology and 
Biotechnology, University of Pécs. Neutrophils were isolated  from fresh anticoagulated 
(EDTA) blood sample by density centrifugation using Polymorphoprep (Axis-Shield, 
Oslo, Norway) containing sodium diatrizoate, 13.8% (w/v), and dextran 500 8.0% (w/v) 
(density, 1.113 g/ml). Five ml of whole blood were layered on 5 ml of Polymorphoprep 
in a 12-ml tube and centrifuged at 500 x g for 30 min at room temperature. The 
neutrophils in the lower band were harvested using a Pasteur pipette and washed twice 
with PBS (containing 0.5% BSA). 
 
III/5.2. Staining the cells with CXCR-1 antibody 
 After the final washing step the viability of the cells was determined using the 
trypan blue dye exclusion test. Then the cells were resuspended in the same buffer to a 
final concentration of 4x106 cells/ml and 25 µl of cells (1x105) were transferred to 5 ml 
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tubes for staining with fluorescein-conjugated anti-human IL-8RA (CXCR-1) mouse 
IgG2a monoclonal antibody (R&D Systems Cat.No. FAB330F). Fluorescein-conjugated 
mouse IgG2a was used as isotype control antibody. The cells were incubated for 30-45 
minutes at 4°C, then washed twice in PBS/BSA buffer to remove unreacted anti-IL-8-
RA antibody. The cells were fixed in PBS/0.1% PFA buffer and stored in dark before 
flow cytometric analysis. 
 
III/5.3. Flow cytometry 
 The samples were run on a FacsCalibur flow cytometer (Becton Dickinson, San 
Jose, CA) using the CellQuest software. 10,000 events were collected from each sample 
and electronic gating was used to eliminate cellular debris from neutrophil cell 
population. Fluorescence histograms (in FL-1 channel) were created from this gate and 
the mean fluorescence intensity of each CXCR-1 labeled sample (referred as mean 
specific staining Mfs) was compared to the mean FL-1 of the isotype control sample as 
background (referred to as mean background fluorescence Mfb). Mean CXCR-1 
fluorescence was determined by calculating the difference between Mfs and Mfb. 
 
III/6. Measurement of serum interleukin-8 
 Serum IL-8 levels were measured with an automated immuno-chemiluminescent 
analyzer (Immulite, DPC) using two-point master calibration and checking the accuracy 
and precision of the method with bi-level independent controls. The detection limit was 
5 pg/ml for IL-8. The measurements were done in Department of Laboratory Medicine, 
University of Pécs. 
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III/7. Other laboratory assessments 
The daily mean blood glucose level was calculated from an average of  21 
measurements (median) (range: 8-43) performed during the hospitalization period of 
three days by a portable meter using capillary blood (D Cont Personal, 77 Elektronika, 
Budapest, Hungary), with a measuring capacity between 1.1-25.5 mmol/l.  
Glycated haemoglobin was measured by HPLC (Bio-Rad Laboratories 
Diagnostic Group, Hercules, California, USA; with 4.0-6.3% normal range).  
Measurements of urinary and serum glucose (at the time of urine sample 
collection) were carried out by GOD/PAP enzymatic colorimetric method (Reanal Rt., 
Budapest, Hungary).  
Albumin excretion was measured in 24 h urine sample by liquid-phase 
immunoprecipitation assay with nephelometric end-point detection (Tubox 
Microalbuminuria Assay, Orion Diagnostica, Finland) and microalbuminuria was 
defined as albumin excretion between 30 and 300 mg/day at least in two of three 
collection performed during the hospitalization period.  
The mean value of blood pressure was calculated from an average of 7 
measurements (median) (range: 2-22) during admission. Blood pressure was measured 
by an automated blood pressure meter (Omron M4, Japan).  
Information was documented regarding the age and duration of diabetes and 
BMI was calculated. Pubertal development was assessed according to Tanner stages: 
prepubertal=Tanner I., pubertal=Tanner II.-IV. and postpubertal=Tanner V. 
 
III/8. Statistics 
 SPSS for Windows 10.0 statistical software was used (Chicago, USA). 
Distributions of data were tested for normality by the Kolmogorov-Smirnov test. Mean 
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± SD are given if the distribution was normal. The distributions of urinary and serum 
interleukin values were not normal, therefore the median and interquartile range (IQR) 
were given. The expression of CXCR-1 was given as mean fluorescence intensity and 
95% confidence interval (CI). For assessing statistically significant differences 
Student′s t test (for normal distribution), Mann-Whitney test or Kruskal-Wallis test (for 
non-normally distributed variables), χ2 test and Fisher’s exact test (for dichotomous 
variables) and Pearson or Spearman correlation were used. To find the optimal 
sensitivity and specificity of urinary IL-8 to predict ASB ROC (receiver operating 
characteristics) analysis was used. The odds ratio (OR) was estimated by logistic 
regression analysis to find the independent risk factors for ASB. p<0.05 was considered 
to be statistically significant. 
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IV. RESULTS 
 
IV/1. Prevalence of asymptomatic bacteriuria in type 1 diabetic children  
 
 The prevalence of ASB was 10.1% (95%CI 5.7-14.5%) which was significantly 
higher in diabetic than in the control group [2.6% (95%CI 0.35-4.8%); (p=0.003), 
Figure 4.]. We did not find any difference in prevalence of ASB between diabetic males 
[9.3% (95%CI 3.2-15.4%)] and females [10.9% (95%CI 4.6-17.2%); (p=0.73), Figure 
5.].  
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Figure 4.: The prevalence of ASB (± 95%CI) in diabetic (black bar) and control children (white 
bar) (p=0.003). 
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Figure 5.: The prevalence of ASB (± 95%CI) in diabetic males (black bar) and females (white 
bar) (p=0.73). 
 
p=0.003 
p=0.73 
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Dividing the participants into two groups according to age, we found that the 
prevalence of ASB was not significantly different in young diabetic and control patients 
(<15 years of age) [6.3% (95%CI 1.4-11.1%) vs. 1.7% (95%CI 0.1-2.3%); p=0.15]. In 
contrast, the prevalence of ASB was higher in the older diabetic subjects (≥15 years of 
age), than among controls [14.6% (95%CI 7.0-22.2%) vs. 3.8% (95%CI 0.2-8.0%); 
p=0.028)]. In this older age-group ASB was twice as common in diabetic girls than in 
boys but this difference was not statistically significant (data not shown). The 
prevalence of ASB in diabetic patients tended to increase with age ≥15 years of age 
[14.6% (95%CI 7.0-22.2%)] vs. <15 years of age [6.3% (95%CI 1.4-11.1%); p=0.064)]. 
There was no history of earlier symptomatic urinary tract infection in participants with 
bacteriuria. 
 
IV/2. Possible causes of asymptomatic bacteriuria 
 
IV/2.1. Metabolic parameters 
 
There was no difference between diabetic patients with and without ASB in age, 
duration of diabetes, BMI and in pubertal development (Table 1.). HbA1C, daily mean 
blood glucose levels, serum glucose at the time of urine sampling and daily urinary 
glucose excretion were also similar (Table 1.). The albumin exretion rate was somewhat 
higher in bacteriuric patients but it remained within the normal range (Table 1.).  
Univariate logistic regression analysis did not find any significant risk factors, 
but HbA1C ≥10% in the multivariate analysis proved to be an independent risk factor for 
ASB (OR: 5.23; p=0.002); (Table 2.). 
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Parameters sterile ASB P 
N 160 18  
Age (yrs) 14.9 ± 5.9 16.9 ± 5.1 0.17 
Duration of DM (yrs) * 6.0 (2.9-9.9) 8.5 (5.1-11.9) 0.067 
BMI (kg/m2) 20.9 ± 4.4 22.0 ± 4.6 0.35 
Systolic BP (mmHg) 109.6 ± 14.0 111.1 ± 10.0 0.6 
Diastolic BP (mmHg) 65.7 ± 7.0 67.8 ± 7.5 0.25 
Prepuberty/puberty/postpuberty (%) 23.1/37.5/39.4 16.7/22.2/61.1 0.2 
Albumin excretion rate (mg/day) * 11.6 (7.4-20.2) 22.7 (9.6-28.9) 0.054 
Daily mean blood glucose (mmol/day) 9.4 ± 2.1 8.6 ± 1.6 0.31 
Morning serum glucose (mmol/l) 12.1 ± 4.6 11.3 ± 4.5 0.5 
Urine glucose excretion (g/day) * 13.6 (5.5-26.5) 13.0 (4.4-26.8) 0.82 
HbA1C (%) *  8.3 (7.3-9.8) 10.0 (7.6-11.1) 0.1 
Leukocyturia (%) 14.4 46.7 0.002 
 
 
Table 1.: Comparisons between diabetic patients with and without ASB. *: median (IQR) is 
given because of the skewed distribution. 
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 Univariate Multivariate 
Variables p OR (95%CI) p OR adjusted for age (95%CI)
Age 0.17 1.06 (0.98-1.15) 0.85 1.01 (0.89-1.15) 
Gender 0.73 1.19 (0.45-3.17) 0.77 1.19 (0.37-3.87) 
Duration of DM <5 yrs  0.21 1 0.26 1 
                      5-10 yrs 0.21 2.28 (0.63-8.18) 0.27 2.65 (0.46-15.1) 
                      >10 yrs 0.08 3.17 (0.87-11.5) 0.1 5.2 (0.72-37.1) 
Microalbuminuria 0.15 2.47 (0.71-8.54) 0.5 1.58 (0.41-6.04) 
HbA1C >10% 0.09 2.41 (0.86-6.76) 0.02 5.23 (1.29-21.3) 
 
Table 2.: Univariate and multivariate analysis of potential host factors associated with ASB in 
diabetic patients. 
 
IV/2.2. Immunological causes – urinary interleukins 
 
IL-6 in the urine was detectable in 39 of 178 controls [21.9% (95%CI 15.8-
28.0%)] and in 24 of 133 [18.0% (95%CI 11.5-24.5%)] diabetic patients (p=0.41). The 
median value of IL-6 was below the detection limits both in diabetic patients and 
control subjects (p=0.31).  
Sixty-three of 133 patients with diabetes [47.4% (95%CI 38.9-55.9%)] and only 
49 of 178 of controls [27.5% (95%CI 20.9-34.1%)] had measurable IL-8 in their urine 
(p=0.001) and IL-8 values were significantly higher in diabetic [<3.1 pg/mg creatinine 
(<3.1-22.3) median (IQR)] than in control patients [<3.1 pg/mg creatinine (<3.1-4.5); 
p=0.001] (Figure 6.). In the diabetic group IL-8 levels were higher in girls [8.5 pg/mg 
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creatinine (<3.1-63.5)] as compared to boys [<3.1 pg/mg creatinine (<3.1-7.5); 
p=0.001]. 
 
 
Figure 6.: Urinary IL-8 levels in control (white bar) and diabetic patients (black bar) (p=0.001). 
Results are presented as boxplot, the horizontal lines inside the bars represent the median, the 
box represents the IQR. The open circles symbolize the outlier values. 
 
In children with ASB the IL-8 levels were similar both in the diabetic [70.0 
pg/mg creatinine (<3.1-474.4)] and in the control group [42.3 pg/mg creatinine (<3.1-
686.6); p=0.8], suggesting that the increased IL-8 levels in the urine were due to 
bacteriuria rather than diabetes itself. Indeed, urinary IL-8 concentration correlated with 
the level of bacteriuria, the more bacteria in the urine the higher the IL-8 value is 
(p=0.001); (Figure 7.). 
p=0.001 
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Figure 7.: Association between urinary IL-8 and the count of cultured bacteria (p=0.001, 
Kruskal-Wallis test). Results are presented as boxplot, the horizontal lines inside the bars 
represent the median, the box represents the IQR. The open circles symbolize the outlier values. 
 
Furthermore, diabetic patients with leukocyturia had higher IL-8 concentration 
[20.9 pg/mg creatinine (<3.1-417.1)] than those without leukocyturia [<3.1 pg/mg 
creatinine (<3.1-14.3); p=0.003]. One would have expected, therefore that the 
prevalence of „IL-8-uria” and the urinary level of IL-8 would be low and comparable in 
both diabetic and control children without ASB. However, it was found that the 
prevalence of „IL-8-uria” was somewhat higher in diabetics without ASB [41.4% 
(95%CI 32.2-50.6%) as compared to controls [27.2% (95%CI 20.6-33.8%); p=0.012].  
IL-8 was detectable in 77.2% (95%CI 59.8-94.6%) of diabetic patients with 
ASB and 41.4% (95%CI 32.2-50.6%) of them without ASB (p=0.002) and median the 
IL-8 level was higher in diabetics with ASB [70.0 pg/mg creatinine (2.5-474.4)] as 
p=0.001 
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compared to those without ASB [<3.1 pg/mg creatinine (<3.1-12.7); p=0.001] (Figure 
8.). 
 
Figure 8.: IL-8 levels in diabetic patients with (black bar) and without ASB (white bar) 
(p=0.001). Results are presented as boxplot, the horizontal lines inside the bars represent the 
median, the box represents the IQR. The open circles symbolize the outlier values. 
 
In  the diabetic group a weak positive correlation was observed between HbA1C 
and detectable IL-8 levels (≥3.1 pg/mg creatinine) (r=0.4; p=0.002), but similar 
association was absent between HbA1C and detectable IL-6 levels (≥4.7 pg/mg 
creatinine) (r=-0.1; p=0.43).  
In the diabetic group there was no difference in IL-8 levels between patients 
with gram-negative [134.6 pg/mg creatinine (5.8-417.1)] and gram-positive bacteriuria 
[70.0 pg/mg creatinine (<3.1-535.3)] (p=0.76). 
 
p=0.001 
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IV/2.3. Expression of CXC-receptor-1 
 
 The expression of CXCR-1 on the surface of neutrophils in type 1 diabetic 
children was significantly lower than that in control group [240.4 (95%CI: 232.2-248.7) 
vs. 256.1 (95%CI: 246.3-266.0); p=0.024] (Figure 9.). There was no difference between 
males and females either in the diabetic [237.5 (95%CI: 224.7-250.3) vs. 242.2 (95%CI: 
231.3-253.4); p= 0.57] or in the control group [259.9 (95%CI: 243.7-276.2) vs. 253.5 
(95%CI: 240.4-266.5); p= 0.52]. CXCR-1 expression in the diabetic group correlated 
with age (r=0.22; p=0.019), duration of diabetes (r=0.21; p=0.025), but not with BMI 
(r=0.01; p=0.99), HbA1C (r=-0.068; p=0.48) and albumin excretion rate (r=0.1; p=0.29). 
 
 
Figure 9.: The mean fluorescence intensity and 95%CI of CXCR-1 are represented in control 
(white bar) and in diabetic groups (black bar) (Student’s t test; p=0.024). 
 
 
p=0.024 
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IV/3. Serum level of interleukin-8 in type 1 diabetic children 
 
 Serum IL-8 was detectable in 46.8% (95%CI 35.8-57.8%) of diabetic and 30.0% 
(95%CI 15.8-44.2%) of healthy children (p=0.07). However, the concentration of IL-8 
was higher in diabetic children [< 5 pg/ml (< 5-6.4 pg/ml)] than in control group [< 5 
pg/ml (< 5-5.2 pg/ml); p=0.025] (Figure 10.). In the diabetic patients there was no 
difference between age, BMI, HbA1C, cholesterol or triglyceride levels and 
microalbuminuria in the subgroups with detectable and non-detectable IL-8 levels 
(Table 3.). The only significant difference was observed in the duration of diabetes. 
Diabetic patients with detectable IL-8 level had longer diabetes duration (9.2 ± 5.3 
years), than those without detectable IL-8 levels (6.5 ± 4.3 years; p=0.018). 
 
Figure 10.: The serum IL-8 concentrations in control (white bar) and diabetic children (black 
bar) are represented as a boxplot. The box shows the interquartile range (25-75%) and the 
whisker cap spreads to 90%. The median line and the 25% line overlap. (Mann-Whitney test, 
p=0.025). 
p=0.025 
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IL-8 Detectable Not detectable p 
Prevalence (%) 46.8 53.2  
Age (years) 15.8 ± 4.4  14.8 ± 4.9 0.38 
Diabetes duration (years) 9.2 ± 5.3 6.5 ± 4.3 0.018 
HbA1C (%) 8.2 ± 2.0 8.1 ± 1.6 0.66 
Cholesterol (mM/l) 4.2 ± 0.8 4.4 ± 0.9 0.55 
Triglyceride (mM/l) 1.0 ± 0.7 1.0 ± 0.4 0.84 
BMI (kg/m2) 22.1 ± 4.4 21.9 ± 5.3 0.88 
Microalbuminuria (%) 18.9 30.9 0.22 
 
 
Table 3.: Parameters of type 1 diabetic children with detectable and undetectable IL-8 levels. 
The prevalence of detectable IL-8 and microalbuminuria are given as percent, the other 
variables are presented as mean ± SD. 
 
Logistic regression analysis revealed that duration of diabetes (OR: 1.16; 
p=0.023) is a significant risk factors of appearance of IL-8 in the serum of patients with 
type 1 diabetes (Table 4.). 
Risk factors OR (95%CI) p 
Age 0.95 (0,85-1.1) 0.48 
Diabetes duration 1.16 (1.02-1.3) 0.023 
HbA1C ( ≥8%) 0.62 (0.24-1.62) 0.33 
BMI 1.03 (0.89-1.19) 0.68 
Microalbuminuria 0.44 (0.13-1.52) 0.19 
 
Table 4.: Risk factors of IL-8 in the serum of type 1 diabetes. 
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IV/4. Bacterial specimens and evaluation of pyuria 
 
 Bacteria cultured in the diabetic group are listed in Table 5. Gram positive and 
Gram negative bacteria were found in 11 and 7 cases, respectively, and the proportion 
of leukocyturia in patients with Gram positive and Gram negative bacteria was 2/11 to 
6/7 (p=0.041), respectively (Table 4.). The frequency of E. coli which is a dominant 
pathogen agent in UTI was low in diabetic children with ASB (in four out of 14 cases). 
In controls, E. coli (n=2), Streptococcus agalactiae, Klebsiella pneumoniae and Proteus 
vulgaris (n=1-1) were cultured. Among bacteriuric controls only one patient with 
Proteus vulgaris had leukocyturia. 
 
Bacteria Gram-staining Case/Σn  Leukocyturia/cases 
S. agalactiae positive 6/18 2/6 
Enterococcus sp. positive 5/18 0/5 
E. coli negative 4/18 4/4 
K. pneumoniae negative 3/18 2/3 
 
Table 5.: Frequency of isolated bacteria and leukocyturia among diabetic patients with ASB. 
 
The frequency of leukocyturia was 17.9% (95%CI 11.5-24.3%) in diabetic 
patients and 7.9% (95%CI 4.1-11.7%) in controls (p=0.006). Leukocyturia without ASB 
also tended to be more frequent in diabetic patients than in controls [14.4% (95%CI 8.2-
20.5%) vs. 7.5% (95%CI 6.4-8.6%); p=0.05].  In the diabetic group, leukocyturia was 
more frequent in patients with ASB [46.7% (95%CI 21.5-71.9%)] as compared to those 
without ASB [14.4% (95%CI 8.2-20.5%); p=0.002] (Table 1.).  
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IV/5. Usefulness of leukocyturia and urinary IL-8 in screening for ASB 
 
In the whole population the sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) of leukocyturia - to diagnose ASB - were 
showed in Table 6.  We estimated the optimal cut-off point of urinary IL-8 level for the 
prediction of ASB by ROC analysis (Figure 11.). Using this method the optimal cut-off 
point of was an IL-8 level of 10.2 pg/mg creatinine. If this value would be used for 
screening, the sensitivity, specificity, PPV and NPV were presented in Table 6. 
 
Figure 11.: Analysis of the optimal cut-off point of IL-8 for screening ASB by ROC analysis. 
Arrow shows the value of 10.2 pg/mg creatinine IL-8, the narrow lines are interpolated to the x 
and y axes to show the sensitivity (70.4%) and the specificity (78.9%). 
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 leukocyturia IL-8  leukocyturia+IL-8
Sensitivity (%) 50.0 70.4 81.5 
Specificity (%) 89.9 78.9 71.8 
PPV (%) 31.7 23.8 21.6 
NPV (%) 95.1 96.5 97.6 
 
Table 6.: The effectiveness of screening methods of ASB. In the case of IL-8 the value of 10.2 
pg/mg creatinine (calculated by ROC analysis) was used as cut-off point. 
 
The sensitivity of „IL-8-uria” is higher than leukocyturia for screening of ASB, 
but the PPV of leukocyturia is better. The sensitivity can be enhanced using 
leukocyturia and „IL-8-uria” together, but the same time specificity would be 
diminished (Table 6.).
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V. DISCUSSION 
 
V/1. Prevalence of ASB 
As described by Geerlings et al. (40) one out of five type 1 diabetic women had 
ASB. In the few studies in diabetic children a low prevalence of about 1% was found 
(42-44). Our clinical experience suggested a much higher prevalence, therefore we 
decided to estimate the prevalence and the possible risk factors of ASB in type 1 
diabetic children. In contrast to studies mentioned above we have found that the 
prevalence of ASB was four-fold higher in diabetic children and young adults as 
compared controls (Figure 4.). It seems unlikely that this was due to contamination 
because the sampling was carried out in the same manner in both diabetic and control 
group and we excluded cultures in which more than one species was grown. One 
possible explanation for the discrepancy between the published prevalence and the one 
we have found could be that urine sampling was different in these studies (42-44). In 
these publications, there was an interval of 5 to 14 days between the two urine 
samplings, and after 7-10 days of the first culture the second samplings were negative in 
about one third of the patients (45). Whereas in our study urine was collected on two 
consecutive mornings.  
The prevalence was higher in both diabetic boys and girls, we could not observe 
the gender difference of ASB (female preponderance), a phenomenon frequency seen in 
diabetic adults (39). However, above 15 years of age the prevalence of ASB was higher 
in diabetic girls, than in boys, but this difference was not statistically significant 
probably because of the fewer count of subjects. 
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It has been also described that the prevalence of ASB increases with age (35, 
39). The prevalence in our study was not significantly different in patients under and 
above of 15 years of age, but it tended to increase with age. 
Several studies in adult diabetic women have shown that the glycemic control 
did not influence the prevalence of ASB (39, 40, 45, 46). Our observation suggests that 
higher HbA1C levels tend to promote ASB. Comparing diabetic patients with and 
without ASB we did not find differences in HbA1C levels, but using multiple regression 
analysis a HbA1C levels above 10% (equivalent to the 75 percentile in this study) did 
increase the risk of the development of ASB (Table 2.).  
It was suggested that peripheral neuropathy, retinopathy and macroalbuminuria 
are significant risk factors for ASB in adult type 1 diabetic women (39, 40, 46, 50). All 
three of these conditions are rare in childhood diabetes because of the relatively short 
duration of diabetes. The albumin excretion rate tended to be elevated in diabetic 
patients with ASB, but the median and IQR of AER was in the normal range in both 
groups (Table 1.). It is possible that the tendency to elevated albumin excretion was due 
to the bacteriuria in our patients. It is known that even a mild infection in the urinary 
tract can cause transient elevation in urinary albumin excretion, therefore at the 
evaluation of microalbuminuria the presence of bacteriuria has also to be taken into 
account (51). 
 
V/2. Urinary interleukins 
Recently, the attention has turned to the features of host defense mechanisms of 
patients with ASB. Cytokines play a major role in mediating the inflammatory process 
in various clinical entities. IL-6 as a heat-shock protein and IL-8 as the main 
chemoattractant have been found in increased concentrations in the urine of non-
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diabetic patients with UTI (including ASB) not only in adults (13, 19), but also in 
children (16, 18).  
However, in a recent study, lower proinflammatory cytokine secretion (IL-6 and 
IL-8) and urinary leukocyte cell count were found in the urine of adult diabetic women 
with ASB compared to healthy women with ASB (62). An impaired host defense 
mechanisms – suggested by these findings - were thought to play an important role in 
the higher susceptibility to ASB in diabetic patients. 
IL-6 was detectable in the urine of only one fifth of both diabetic and control 
children in our study and the median value was similarly below the detection limit in 
both groups. In diabetic children with ASB urinary IL-6 concentration was similar to 
those of non-diabetic controls. 
However, the IL-8 response was more frequent in diabetic patients than in 
controls and the median value of IL-8 was also higher in the diabetic subjects (Figure 
6.). Diabetic patients and controls with ASB, however, had similar IL-8 levels 
suggesting that the host defense mechanisms associated with urinary interleukins was 
not diminished in type 1 diabetic children and young adults. 
Interestingly, we have also found detectable IL-8 values in individuals (both 
diabetic and control patients) without ASB. There are several possible explanations for 
this phenomenon. Hang et al. have observed that the epithelial cells of the urinary tract 
had significant IL-8 staining by monoclonal antibodies but in contrast to the significant 
marking of the cells, IL-8 was not always measurable in the urine. According to their in 
vitro experiments the IL-8 production by the epithelium seemed to be constitutive and 
the secretion can be induced by different noxious agents entering the urinary tract (15). 
Another possible explanation of this finding could simply be the definition of „sterile” 
urine: bacterial count less than 105 CFU/ml. In other words, individuals labeled 
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„without ABS” based on this definition could still have bacterial counts which were low 
but sufficient enough to produce some IL-8 production. Furthermore, in patients with 
contaminated cultures the urinary IL-8 level was higher than in „no-bacteriuria” group 
and was in the range similar to that in ASB group (data not shown).   
 
V/3. Leukocyte CXCR-1 expression and serum IL-8 concentrations 
We have demonstrated a decreased CXCR-1 expression on the neutrophils of 
children and young adults with type 1 diabetes as compared to healthy controls. It 
seemed that the expression of CXCR-1 was not influenced by metabolic parameters, 
including HbA1C, but correlated with age and duration of diabetes. Regarding the age-
dependency of CXCR-1 expression in type 1 diabetes, it is important to note, that if the 
confounding effect of diabetes duration was excluded using partial correlation analysis, 
the correlation between age and CXCR-1 expression disappeared. This correlation was 
not observed in the control group (data not shown). Therefore, it seems that not age per 
se, but diabetes duration could influence the CXCR-1 expression.  
Frendéus et al. examined the neutrophils of children with recurrent 
pyelonephritis in an infection-free period and demonstrated a decreased CXCR-1 
expression (29). The decreased CXCR-1 expression could lead to diminished neutrophil 
function and could be one possible factor in the susceptibility to infections in diabetes.  
In an attempt to find a possible explanation for the lower CXCR-1 expression in 
diabetes we studied the serum concentration of the selective ligand of CXCR-1, namely 
IL-8. In agreement with a recent study, higher IL-8 level was found in diabetic children 
than healthy controls (63, 64). We have also observed an association between diabetes 
duration and IL-8 levels, supporting the hypothesis, that there is a low grade 
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inflammation in diabetic patients even in the absence of micro- or macrovascular 
complications (65). 
The effect of hyperglycaemia on IL-8 secretion was investigated in the in vitro 
study of Temaru et al. (66). They have shown an enhanced IL-8 messenger RNA 
production by human aortic endothelial cells, but not by smooth muscle cells as a 
response to increasing glucose concentrations. In our study, HbA1C did not seem to 
influence the serum IL-8 levels in diabetes. However, short hyperglycaemic periods - 
which are often found in type 1 diabetic children and not necessarily reflected in HbA1C 
levels - may have contributed to the elevated IL-8 concentration.  
Furthermore there is also known that diabetic ketoacidosis causes elevation of 
serum level of many cytokines including IL-8. The increase of IL-8 concentration was 
pronounced after 6-8 hours of the initial treatment and normalized at the 5th day of 
therapy. The authors considered this observation as a part of a hyperinflammatory 
response accompanying diabetic ketoacidosis (67). Our observations were made in 
diabetic patients without ketoacidosis, but we measured the IL-8 level of few subjects 
with ketoacidosis and found similar tendency of IL-8 kinetics cited above (unpublished 
observation). 
The significance of the lower CXCR-1 expression in type 1 diabetic children is 
not yet known. Neutrophils of healthy subjects stimulated by bacterial antigens in vitro, 
especially by lipopolysaccharide (LPS) have shown a quick and sustained down-
modulation of CXC-receptors within a few minutes after adding the stimulant (68, 69). 
The down-regulation of CXC-receptors were studied in many pathological 
circumstances. In sepsis (25), inflammatory arthritis (70), asthma (26) and Helicobacter 
infection (27) the down-modulation of CXC-receptors were more prominent than in 
control group contributing to the depressed host defense mechanisms. There are no data 
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available on the kinetics of CXC-receptors expression in diabetic subjects after stimuli 
by different pathogenic agents.  
The measurements of CXCR-1 expression and IL-8 level were performed in 
different cohorts of diabetic and non-diabetic individuals, therefore the interpretations 
of the results have limitations. However, the sex ratio, the age, the duration of diabetes 
and the glycated Hb level were similar in the different cohorts. 
 
V/4.Types of bacteria in the urine and lekocyturia  
In UTI the most common bacterium is usually E. coli, which was isolated in 
about 80-90% of positive cultures (1, 4). In our diabetic patients with ASB E. coli was 
found in only about a quarter of positive cases (Table 3.). Similar rates were found in 
adult type 1 diabetic women with ASB (40). It seems therefore, that the spectrum of 
pathogenic bacteria causing ASB and UTI is different. This may be due to the different 
virulence factors in ASB and UTI. E. coli strains causing ASB had fewer virulence 
factors than those causing UTI. P fimbriae - the main virulence factor of E. coli being 
responsible to the adherence of the bacteria to the uroepithelium - were expressed in 
46% of specimens isolated from patients with UTI, but were not detectable in strains in 
patients with ASB. These strains were mainly not able to adhere to the uroepithelium, at 
all (71). 
According to our observation gram-negative bacteria were present in only 38.8% 
and gram-positive species in 61.2% of the cases. The IL-8 levels were similar in urines 
with gram-negative and positive bacteria also suggesting that gram-positive bacteria (S. 
agalactiae, Enterococcus sp.) in the urine of a diabetic patient can induce secretion of 
interleukines by stimulation of the uroepithelial cells. Therefore, we can assume that 
gram-positive bacteria can also be pathogenic in the urinary tract. 
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The frequency of leukocyturia was also higher in diabetic children than in 
controls. Nearly half of our bacteriuric diabetic patients had leukocyturia. A similar 
finding was described in adult diabetic women (40, 72). To estimate the sensitivity, 
specificity, PPV and NPV of leukocyturia we combined the microscopic findings and 
the dip-slide test (leukocyte-esterase). In accordance with others using leukocyte-
esterase test (72, 73) a sensitivity of 50.0% and a PPV of 31.7% was reached. A 
sensitivity and PPV of this magnitude is not sufficient to reliably identify diabetic 
patients with ASB. Therefore we also examined the urinary IL-8 as a possible predictor 
of ASB in diabetes. By means of ROC analysis we have reached a much better 
sensitivity (70.4%) for IL-8, but similar PPV as in the case of leukocyturia, similarly to 
other studies (73). The cause of the lower PPV could be explained by its earlier release 
from the site of infection, earlier disappearing from the urine than PMNs or bacteria or 
inflammation elsewhere in the body (15). 
The association between the number of polymorphonuclear leukocyte and the 
urinary IL-8 is well known (11, 13). In a recent study, a lower urinary leukocytes cell 
count was found in diabetic women and therefore a moderate immune responses were 
presumed in diabetes explaining the higher susceptibility to urinary tract infections (62). 
We did not have the possibility to count the exact number of PMNs in the urine, only 
the leukocyturia was recorded. We found higher IL-8 level in individuals with 
leukocyturia which shows an intact „IL-8-PMNs” axis in the urinary tract of a type 1 
diabetic children. 
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VI. SUMMARY OF NEW OBSERVATIONS 
 
 We have found that the prevalence of ASB is four-fold higher in diabetic children and 
young adults than in controls. Gender difference is not remarkable. Poor glycemic 
control (HbA1C ≥10%) appears to be a significant risk factor.  
 
 There is no impairment in urinary cytokine network (including IL-6 and IL-8) in 
diabetic children with ASB. 
 
 Low grade inflammatory state – presented by elevated serum IL-8 concentration - in 
type 1 diabetes may cause down-regulation of CXCR-1, therefore it could contribute to 
the enhanced susceptibility to several infections in diabetic patients. Further 
investigations are needed to reveal the kinetics of CXCR-1 expression and understand 
the clinical importance of this observation. 
 
 The spectrum of pathogenic bacteria in ASB differs from the usual spectrum of UTI, 
not only gram negative but gram positive strains are also present.  
 
 Urinary IL-8 together with determination of leukocyturia had good sensitivity to 
screen ASB, unfortunately the positive predictive values of these methods are low. 
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VII.ABBREVIATIONS 
 
AER:  albumin exretion rate 
ASB:  asymptomatic bacteriuria 
CFU:  colony-forming units 
CXCR-1: CXC-receptor-1 
HbA1C: hemoglobin A1C 
hpf:  high-power field 
IL-6:  interleukin-6 
IL-8:  interleukin-8 
LPS:  lipopolysaccharide 
NPV:  negative predictive value 
PMNs:  polymorphonuclear leukocytes 
PPV:  positive predictive value 
ROC:  receiver operating charecteristics 
RR:  relative risk 
THP:  Tamm-Horsfall protein 
TLRs:  Toll-like receptors 
UTI:  urinary tract infection 
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